南方医科大学学报 ›› 2012, Vol. 32 ›› Issue (11): 1568-.

• • 上一篇    下一篇

miR-199a在肾细胞癌中的表达与临床病理特征及预后的关系

司彤,刘春晓,许凯,桂耀庭   

  • 出版日期:2012-11-20 发布日期:2012-11-20

Association of miR-199a expression with clinicopathologic characteristics and prognosis of renal cell carcinoma

  • Online:2012-11-20 Published:2012-11-20

摘要: 目的检测miR-199a在肾细胞癌及癌旁相对正常肾组织中的表达量,分析其相对表达量和肾细胞癌相关的临床病理特征
及其对肾细胞癌预后判断的意义。方法采用RT-qPCR检测67例肾细胞癌及癌旁正常组织miR-199a表达,分析表达的差异与
临床病理特征间的关系。结果在肾细胞癌和癌旁相对组织中均有不同程度的表达,在肾细胞癌的表达显著低于癌旁相对正常
组织,均值13.7倍(P=0.003)。miR-199a的表达在不同肿瘤浸润程度及复发程度之间存在差别(P<0.05,χ2=4.215),
而与年龄、组织学类型、淋巴结转移、远处转移、Fuhrman分级等无统计学关联(P>0.05)。miR-199a下调组生存期明显低于对照组(Log-rank
test,P=0.017)。结论miR-199a表达下调与肾癌患者原发肿瘤浸润程度、复发及预后不良有关,可作为评估肾癌预后有价值的
一种指标。

Abstract: ObjectiveTo investigate the association of miR-199a expression with the clinicopathologic characteristics and the
survival of patients with renal cell carcinoma (RCC). MethodsReal-time quantitative RT-PCR was used to detect the
expression of miR-199a in the tumor tissues and paired adjacent normal tissues from67patients with RCC. The correlations of
miR-199a expression with the clinicopathologic characteristics and survival of RCC patients were analyzed.ResultsPositive
miR-199a expression was detected in both the RCC and adjacent normal tissues, but the tumor tissues showed a significantly
lower expression level by a mean of 13.7folds (P=0.003). The expression of miR-199a was negatively correlated with tumor
recurrence in RCC patients in T stage (P<0.05), but showed no significant correlations with the patients’age, histological type
of the tumor, lymph node metastasis, distal metastasis, or Fuhrman grade (P>0.05). The patients with lowered miR-199a
expression in the tumor tissue had a significantly shorter mean survival time than those without miR-199a down-regulation (P=
0.017by Log-rank test).ConclusionA decreased expression of miR-199a is significantly correlated with a higher tumor stage, a
greater likeliness of tumor recurrence, and a poorer prognosis in RCC patients. miR-199a can serve as a promising prognostic
factor of renal cell carcinoma.